Infections due to multidrug resistant Gram-negative pathogens are of great concern worldwide, as they are frequently associated with high mortality and morbidity rates. The occurrence of Pseudomonas spp. producing Klebsiella pneumoniae carbapenemases (KPCs) imposes a great challenge through treatment course of bloodstream infections (BSIs). Pseudomonas putida has been recognized as an emerging pathogen of healthcare associated infections (HAIs). Therefore, we aimed to report a case of a non-fatal case of peripheral line associated BSI (PLA-BSI) in an immunocompromised host due to P. putida harboring blaKPC-2 gene in Brazil. A P. putida isolate was recovered from a blood culture of a 72-year-old man admitted at a University Hospital, identified by BD Phoenix™ 100 (Becton, Dickinson and Company), causing PLA-BSI. The species identification was confirmed by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS) and resistance to carbapenems were confirmed by Epsilometer test (E-test®). Additionally, the presence of important carbapenemases genes (blaKPC, blaNDM, blaOXA-48-like, blaSPM, blaIMP, blaVIM) was investigated by Polymerase Chain Reaction. The bacterial isolate was confirmed as meropenem resistant P. putida harboring blaKPC-2 gene.Thereofre, these fidings suggest that P. putida can work as a reservoir for resistance genes as this bacterium has the ability to disseminate through water-fluids inside hospital and community settings. Moreover, this paper highlights that a frequent and worldwide disseminated mechanism of resistance (blaKPC-2) is currently occurring among uncommon agents of BSI.
Due to bacterial resistance to antimicrobials, antibiotic therapy for urinary tract infections (UTIs) has become a major challenge for clinicians. The present work aimed to compare the antimicrobial susceptibility profiles of 53 uropathogenic Escherichia coli (UPEC) isolates, assessed using the disk diffusion method and two automated systems (PHOENIX BD™ and VITEK2), with interpretations based on CLSI and BrCAST guidelines. Twenty-five antibiotics were tested to assess differences in susceptibility profiles. Statistical tools, including Kappa coefficient analysis and chi-square tests, were applied to assess concordance and significance between methods. Among the main discrepancies found, BrCAST has classified a greater number of UPEC isolates as resistant to more than half of the antibiotics tested by the disk diffusion method, when compared to CLSI. Although faster, the PHOENIX BD and VITEK2 automated systems exhibited significant discrepancies, with divergences observed for half of the antimicrobials tested. Both automated methods showed discrepancies compared to the disk diffusion method under CLSI and BrCAST guidelines. PHOENIX BD classified some isolates resistant by DD/CLSI as susceptible, while VITEK2 misclassified 25% to 50% of the antimicrobials tested. Conversely, VITEK2 also classified some isolates susceptible to DD/CLSI as resistant to 25% of the antimicrobials tested. Regarding DD/BrCAST, PHOENIX BD classified resistant isolates as susceptible (to 50% of the antimicrobials tested). In comparison, VITEK2 classified resistant isolates as susceptible and susceptible isolates as resistant (25% of the antimicrobials for both). These findings highlight the need for careful selection of susceptibility testing methods, as variations in interpretive criteria between CLSI and BrCAST could impact clinical decision-making. This study underscores the importance of methodological consistency in accurately informing antibiotic therapy in UTI management, especially in the face of rising resistance.
Background/Objectives: Uropathogenic Escherichia coli (UPEC) is the leading cause of urinary tract infections in both community and hospital settings worldwide. Antimicrobial-resistant UPEC strains pose a significant challenge for effective antibiotic therapy. In this study, 50 bacterial isolates recovered from urine samples of patients attended in different sectors of a public hospital in Rio de Janeiro over five months were analyzed to assess antimicrobial resistance and virulence profiles through broad gene screening. Methods: Biofilm production was assessed using a semi-quantitative adherence assay. PCR was employed to investigate 27 resistance genes, 6 virulence genes, sequence types (STs), and phylogroups. Susceptibility to 25 antimicrobial agents was determined by disk diffusion testing. Furthermore, the pathogenic potential was evaluated in vivo using the Tenebrio molitor larvae infection model. Results: Most UPEC isolates were moderate or strong biofilm producers (41/50; 82%). The sul1 and sul2 resistance genes were the most frequently detected (58%). Two virulence gene patterns were identified: fyuA, iutA, fimH, cnf1 and fyuA, iutA, fimH (13 isolates; 26%). ST131 and ST73 were the most common sequence types (16% each), and phylogroup B2 was the most prevalent (50%). Thirty isolates (60%) were multidrug-resistant, most of which belonged to phylogroup B2. UPEC exhibited dose-dependent lethality, causing 100% mortality at 2.6 × 108 CFU/mL within 24 h. Conclusions: These findings reinforce the urgent need for surveillance strategies and effective antimicrobial stewardship in clinical practice.
The present study aims to investigate two of the Uropathogenic Escherichia coli (UPEC) pathogenesis mechanisms, as adherence and invasion in primate kidney epithelial (Vero) cells. Methods: 20 E. coli isolates from outpatients with UTI in one public clinic were evaluated for adherence and invasive abilities in Vero cells. Results: All 18 positive isolates for fimH gene adhered to the Vero cells (100%). The two UPEC isolates that did not carry the fimH gene did not adhere. Two different UPEC adherence patterns were observed: aggregative adherence pattern (AA) and a pattern called “no typical adherence pattern” (NTA). Among 18 adherent UPEC isolates, 11 presented AA adherence pattern (61%) and 7 showed NTA pattern (39%). The high rate of adherence of the UPEC fimH positive isolates (≅90%) to Vero cells suggests the expression and participation of the FimH adhesin in UPEC adherence behavior. Invasive capacity of UPEC isolates ranged of about 6.5% to 15.33%. Results corroborate the fact that UPEC can persist in the urinary tract through its adhesion, as well as invade cells establishing the bacterial UTI process.